Improving Health, Health Care and Quality of Life

DaVita 3rd Quarter 2012 Results

DENVER--(BUSINESS WIRE)--Oct. 30, 2012-- DaVita Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2012. Net income attributable to DaVita Inc. for the three and nine months ended September 30, 2012 was $144.7 million and $427.8 million, or $1.50 per share and$4.46 per share, respectively, excluding for the nine months ended September 30, 2012 an after-tax legal proceeding contingency accrual and related expense of $47.6 million, or $0.50 per share, that occurred in the second quarter of 2012. Net income attributable to DaVita Inc. for the nine months ended September 30, 2012 including this item was $380.2 million, or $3.96 per share.

Our operating results for the three and nine months ended September 30, 2012, include an additional$5.4 million of after-tax debt expense, or $0.06 per share, resulting from the proposed amendments under our senior secured credit facilities as well as issuing the New Senior Notes in advance of the potential acquisition of HCP.

Net income attributable to DaVita Inc. for the three and nine months ended September 30, 2011 was$135.4 million and $344.3 million, or $1.42 per share and $3.54 per share, respectively, excluding for the nine months ended September 30, 2011 an after-tax non-cash goodwill impairment charge of approximately $14.4 million, or $0.14 per share, that was recorded in the second quarter of 2011 related to our infusion therapy business. Net income attributable to DaVita Inc. for the nine months ended September 30, 2011 including this item was $329.9 million or $3.40 per share.

Financial and operating highlights include:

  • Cash Flow: For the rolling twelve months ended September 30, 2012, operating cash flow was $1,051 millionand free cash flow was $665 million. For the three months ended September 30, 2012, operating cash flow was$367 million and free cash flow was $271 million. For a definition of free cash flow see Note 4 to the reconciliations of non-GAAP measures.
  • Operating Income: Operating income for the three and nine months ended September 30, 2012 was $341 million and $987 million, respectively, excluding for the nine months ended September 30, 2012 the pre-tax legal proceeding contingency accrual and related expenses of $78 million. Operating income for the nine months ended September 30, 2012 including this item was $909 million.

Operating income for the three and nine months ended September 30, 2011 was $319 million and$825 million, respectively, excluding for the nine months ended September 30, 2011 the pre-tax non-cash goodwill impairment charge of $24 million. Operating income for the nine months endedSeptember 30, 2011 including this item was $801 million.

  • Volume: Total U.S. treatments for the third quarter of 2012 were 5,550,645, or 71,162 treatments per day, representing a per day increase of 12.3% over the third quarter of 2011. Non-acquired treatment growth, as well as our normalized non-acquired treatment growth in the quarter, were both 4.4% over the prior year’s third quarter.
  • Effective Tax Rate: Our effective tax rate was 36.4% for both the three and nine months ended September 30, 2012, respectively. This effective tax rate is impacted by the amount of third party owners’ income attributable to non-tax paying entities. The effective tax rate attributable to DaVita Inc. was 40.5% and 40.8% for the three and nine months ended September 30, 2012, respectively. We still expect our 2012 effective tax rate attributable toDaVita Inc. to be in the range of 40.0% to 41.0%.
  • Acquisition: As previously announced on May 21, 2012, we entered into a definitive merger agreement to acquire HealthCare Partners (HCP), one of the country’s largest operators of medical groups and physician networks. The total purchase price to be paid by DaVita Inc. will consist of $3.66 billion in cash and approximately 9.38 million shares of DaVita common stock, subject to post-close adjustments. In addition to the total merger consideration payable at close, DaVita will pay to the owners of HCP a total of up to $275 million of additional cash consideration in the form of two separate earn-out payments if certain financial performance targets are achieved by HCP in 2012 and 2013. We expect the transaction to close in early November 2012and anticipate HCP operating results will be included in our consolidated operating results beginning inNovember 2012.
  • Debt Transactions: As previously announced, in August 2012 we entered into amendments to our existing senior secured credit facilities to permit additional borrowings under the credit agreement in an aggregate principal amount of $3.0 billion to be used to finance a portion of the HCP transaction. For further details regarding these amendments, see our SEC filing on Form 8-K dated August 28, 2012.

On August 28, 2012 we issued $1.25 billion aggregate principal amount of 5 ¾% senior notes due 2022 (New Senior Notes). All of the proceeds from the issuance of the New Senior Notes along with related fees and interest through November 30, 2012 were deposited into escrow pending the consummation of the HCP acquisition. For further details regarding this transaction, see our SEC filings on Form 8-K dated August 28, 2012 and August 16, 2012.

  • Center Activity: As of September 30, 2012, we operated or provided administrative services at 1,912 outpatient dialysis centers located in the United States serving approximately 150,000 patients and 24 outpatient dialysis centers serving approximately 1,200 patients that are located in five countries outside of the United States. During the third quarter of 2012, we acquired 10 centers and opened a total of 21 centers located in the United States. We also opened two centers and provided administrative services to three additional centers outside of the United States.

Outlook

We are updating our operating income guidance for 2012 for our dialysis services and related ancillary businesses to now be in the range of $1,315 million to $1,330 million. Our previous operating income guidance for our dialysis services and related ancillary businesses was in the range of $1,275 million to $1,325 million. Following the expected close of the HCP acquisition in early November 2012, we expect the incremental operating income contribution from HCP to be in the range of $25 million to$30 million per month for the remainder of the year. Our operating income guidance for our dialysis services and related ancillary businesses for 2012 excludes the legal proceeding contingency accrual and related expenses of $78 million and transaction expenses related to the HCP acquisition.

Our consolidated operating income guidance for 2013 is expected to be in the range of $1,750 million to $1,900 million including the operating results of HCP. Our operating income guidance for 2013 for our dialysis services and related ancillary businesses is expected to be in the range of $1,350 million to $1,450 million and our operating income guidance for 2013 for HCP is expected to be in the range of $400 million to $450 million. We also expect our consolidated operating cash flows for 2013 to be in the range of $1,350 million to $1,500 million. These projections and the underlying assumptions involve significant risks and uncertainties, including those described below, and actual results may vary significantly from these current projections.

We will be holding a conference call to discuss our results for the third quarter ended September 30, 2012 on October 30, 2012 at 5:00 p.m. Eastern Time. The dial in number is 800-399-4406. A replay of the conference call will be available on DaVita’s official web page, www.davita.com, for the following 30 days.

This release contains forward-looking statements, within the meaning of the federal securities laws, including statements related to our guidance and expectations for our 2012 and 2013 operating income, our 2013 operating cash flows and our 2012 effective tax rate attributable to DaVita Inc., and the anticipated timing and closing of the HCP transaction. Factors that could impact future results include the uncertainties associated with governmental regulations, general economic and other market conditions, competition, accounting estimates, the variability of our cash flows and the risk factors set forth in our SEC filings, including our quarterly report on Form 10-Q for the quarter endedJune 30, 2012 and subsequent quarterly reports to be filed on Form 10-Q or current reports on Form 8-K. The forward-looking statements should be considered in light of these risks and uncertainties.

These risks and uncertainties include those relating to:

  • the concentration of profits generated from commercial payor plans,
  • continued downward pressure on average realized payment rates from commercial payors, which may result in the loss of revenues or patients,
  • a reduction in the number of patients under higher-paying commercial plans,
  • a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs,
  • the impact of health care reform legislation that was enacted in the United States in March 2010,
  • changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing,
  • our ability to maintain contracts with physician medical directors,
  • legal compliance risks, including our continued compliance with complex government regulations,
  • current or potential investigations by various government entities and related government or private-party proceedings,
  • continued increased competition from large and medium-sized dialysis providers that compete directly with us,
  • the emergence of new models of care introduced by the government or private sector, such as accountable care organizations, independent practice association and integrated delivery systems, and changing affiliation models for physicians plans, such as employment by hospitals, that may erode our patient base and reimbursement rates,
  • our ability to complete any acquisitions or mergers, including the consummation of the HCP transaction, dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire, including the HCP business, or to expand our operations and services to markets outside the United States, or to businesses outside of dialysis,
  • variability of DaVita’s cash flows, or
  • risks arising from the use of accounting estimates in our financial statements.

In addition, upon closing of the HCP transaction, certain other risks and uncertainties related to HCP will also affect these forward-looking statements, including those relating to:

  • the loss of key HCP employees following the HCP transaction,
  • potential disruption from the HCP transaction making it more difficult to maintain business and operational relationships with customers, partners, affiliated physicians and physician groups and others,
  • the risk that the cost of providing services under HCP’s agreements will exceed HCP’s compensation,
  • the risk that laws regulating the corporate practice of medicine could restrict the manner in which HCP conducts its business,
  • the risk that reductions in reimbursement rates and future regulations may negatively impact HCP’s business, revenue and profitability,
  • the risk that HCP may not be able to successfully establish a presence in new geographic regions,
  • the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP’s business,
  • the fact that HCP faces certain competitive threats that could reduce its profitability, or
  • the risk that a disruption in HCP’s healthcare provider networks could have an adverse effect on HCP’s operations and profitability.

We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

This release contains non-GAAP financial measures. For reconciliations of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the attached reconciliation schedules. For the reasons stated in the reconciliation schedules, we believe our presentation of non-GAAP financial measures provides useful supplemental information for investors.

 
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(dollars in thousands, except per share data)
 
    Three months ended   Nine months ended
    September 30,   September 30,
    2012   2011   2012   2011
Dialysis patient service operating revenues   $ 1,838,363     $ 1,669,086     $ 5,410,200     $ 4,749,469  
Less: Provision for uncollectible accounts related to patient service operating revenues     (59,803 )     (50,039 )     (167,227 )     (138,520 )
Net patient service operating revenues     1,778,560       1,619,047       5,242,973       4,610,949  
Other revenues     184,406       138,783       516,368       370,427  
Total net operating revenues     1,962,966       1,757,830       5,759,341       4,981,376  
Operating expenses and charges:                
Patient care costs     1,340,918       1,189,638       3,916,324       3,466,860  
General and administrative     201,198       182,638       623,208       498,033  
Depreciation and amortization     80,586       67,558       234,368       193,641  
Provision for uncollectible accounts     2,469       1,903       6,294       4,727  
Equity investment income     (3,064 )     (2,619 )     (8,314 )     (6,555 )
Legal proceeding contingency accrual and related expenses         78,000    
Goodwill impairment charge           24,000  
Total operating expenses and charges     1,622,107       1,439,118       4,849,880       4,180,706  
Operating income     340,859       318,712       909,461       800,670  
Debt expense    

(70,494

)

   

(60,848

)

   

(192,584

)

   

(179,340

)

Other income     819       798       2,698       2,195  
Income from continuing operations before income taxes     271,184       258,662       719,575       623,525  
Income tax expense     98,634       94,204       262,138       224,034  
Income from continuing operations     172,550       164,458       457,437       399,491  
Discontinued operations:                
Income from operations of discontinued operations, net of tax       1,076         1,460  
Loss on disposal of discontinued operations, net of tax      

(3,688

)

     

(3,688

)

Net income     172,550       161,846       457,437       397,263  

Less: Net income attributable to noncontrolling interests

   

(27,829

)

   

(26,485

)

   

(77,259

)

   

(67,385

)

Net income attributable to DaVita Inc.   $ 144,721     $ 135,361     $ 380,178     $ 329,878  
Earnings per share:                
Basic income from continuing operations per share attributable to DaVita Inc.   $ 1.52     $ 1.48     $ 4.03     $ 3.50  
Basic net income per share attributable to DaVita Inc.   $ 1.52     $ 1.45     $ 4.03     $ 3.47  
Diluted income from continuing operations per share attributable to DaVita Inc.   $ 1.50     $ 1.45     $ 3.96     $ 3.43  
Diluted net income per share attributable to DaVita Inc.   $ 1.50     $ 1.42     $ 3.96     $ 3.40  
Weighted average shares for earnings per share:                
Basic     94,979,858       93,441,620       94,309,099       95,053,339  
Diluted     96,634,620       95,171,225       96,124,226       97,057,773  
Amounts attributable to DaVita Inc.:                
Income from continuing operations   $ 144,721     $ 138,192     $ 380,178     $ 332,325  
Discontinued operations      

(2,831

)

     

(2,447

)

Net income   $ 144,721     $ 135,361     $ 380,178     $ 329,878  
 
 
DAVITA INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)

(dollars in thousands, except per share data)

 
    Three months ended   Nine months ended
    September 30,   September 30,
    2012   2011   2012   2011
Net income   $ 172,550     $ 161,846     $ 457,437     $ 397,263  
Other comprehensive (loss) income, net of tax:                
Unrealized losses on interest rate swap and cap agreements:                
                 
Unrealized losses on interest rate swap and cap agreements     (1,741 )     (10,869 )     (6,104 )     (27,839 )
Less: Reclassifications of net swap and cap agreements realized losses into net income     2,530       2,702       7,586       7,124  
                 
Unrealized gains (losses) on investments:                
Unrealized gains (losses) on investments     445       (902 )     1,387       (587 )
Less: Reclassification of net investment realized gains into net income         (75 )     (57 )
                 
Foreign currency translation adjustments     (135 )       (1,593 )  
Other comprehensive income (loss)     1,099       (9,069 )     1,201       (21,359 )
                 
Total comprehensive income     173,649       152,777       458,638       375,904  
Less: Comprehensive income attributable to the noncontrolling interests     (27,829 )     (26,485 )     (77,259 )     (67,385 )
Comprehensive income attributable to DaVita Inc.   $ 145,820     $ 126,292     $ 381,379     $ 308,519  
 
 
DAVITA INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(dollars in thousands)
 
    Nine months ended
    September 30,
    2012   2011
Cash flows from operating activities:          
Net income   $ 457,437     $ 397,263  
Adjustments to reconcile net income to cash provided by operating activities:          
Depreciation and amortization     234,368       194,328  
Stock-based compensation expense     34,857       36,392  
Tax benefits from stock award exercises     60,252       35,096  
Excess tax benefits from stock award exercises    

(39,346

)

   

(19,640

)

Deferred income taxes    

(1,374

)

    38,377  
Equity investment income, net     10       238  
Other non-cash charges and loss on disposal of assets     17,244       16,398  
Goodwill impairment charge       24,000  
Changes in operating assets and liabilities, other than from acquisitions and divestitures:          
Accounts receivable    

(51,349

)

   

(61,483

)

Inventories     1,958       11,767  
Other receivables and other current assets     65,047       81,737  
Other long-term assets     3,429       2,408  
Accounts payable     (18,200 )     56,652  
Accrued compensation and benefits     113,101       121,631  
Other current liabilities     87,223      

(8,733

)

Income taxes    

(69,108

)

    88,454  
Other long-term liabilities     5,064       14,502  
Net cash provided by operating activities     900,613       1,029,387  
Cash flows from investing activities:          
Additions of property and equipment, net    

(378,949

)

   

(251,879

)

Acquisitions    

(419,114

)

    (927,124 )
Proceeds from asset sales     2,118       51,623  
Purchase of investments available for sale     (3,452 )     (2,118 )
Purchase of investments held-to-maturity     (5,257 )     (29,740 )
Proceeds from sale of investments available for sale     6,796       1,149  
Proceeds from maturities of investments held-to-maturity     12,375       29,747  
Purchase of equity investments and other assets     (1,276 )     (5,005 )
Distributions received on equity investments     2       340  
Net cash used in investing activities     (786,757 )     (1,133,007 )
Cash flows from financing activities:          
Borrowings     26,992,105       27,506,051  
Payments on long-term debt     (25,799,807 )     (27,350,513 )
Restricted cash     (1,268,767 )    
Interest rate cap premiums and other deferred financing costs     (22,189 )     (17,863 )
Purchase of treasury stock       (323,348 )
Distributions to noncontrolling interests     (81,978 )     (67,408 )
Stock award exercises and other share issuances, net     8,395       9,886  
Excess tax benefits from stock award exercises     39,346       19,640  
Contributions from noncontrolling interests     19,368       14,779  
Proceeds from sales of additional noncontrolling interests     1,844       2,675  
Purchases from noncontrolling interests     (13,774 )     (9,190 )
Net cash used in financing activities     (125,457 )     (215,291 )
Effect of exchange rate changes on cash and cash equivalents     43      
Net decrease in cash and cash equivalents     (11,558 )     (318,911 )
Cash and cash equivalents at beginning of period     393,752       860,117  
Cash and cash equivalents at end of period   $ 382,194     $ 541,206  
 
 
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(dollars in thousands, except per share data)
 
    September 30,     December 31,  
    2012     2011  
ASSETS            
Cash and cash equivalents   $ 382,194     $ 393,752  
Short-term investments     5,836       17,399  
Accounts receivable, less allowance of $232,127 and $250,343     1,248,050       1,195,163  
Inventories     78,322       75,731  
Other receivables     207,439       269,832  
Other current assets     46,989       49,349  
Income tax receivable     33,625      
Deferred income taxes     323,219       280,382  
Total current assets     2,325,674       2,281,608  
Property and equipment, net     1,654,657       1,432,651  
Amortizable intangibles, net     177,542       159,491  
Equity investments     28,705       27,325  
Long-term investments     13,249       9,890  
Other long-term assets     30,558       34,231  
Restricted cash     1,268,767      
Goodwill     5,324,960       4,946,976  
    $ 10,824,112     $ 8,892,172  
LIABILITIES AND EQUITY            
Accounts payable   $ 272,627     $ 289,653  
Other liabilities     416,897       325,734  
Accrued compensation and benefits     529,492       412,972  
Current portion of long-term debt     117,821       87,345  
Income tax payable         37,412  
Total current liabilities     1,336,837       1,153,116  
Long-term debt     5,620,716       4,417,624  
Other long-term liabilities     145,246       132,006  
Alliance and product supply agreement, net     15,990       19,987  
Deferred income taxes     484,918       423,098  
Total liabilities     7,603,707       6,145,831  
Commitments and contingencies            
Noncontrolling interests subject to put provisions     550,020       478,216  
Equity:            
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)            
Common stock ($0.001 par value, 450,000,000 shares authorized; 134,862,283 shares issued; 95,346,980 and 93,641,363 shares outstanding)     135       135  
Additional paid-in capital     543,751       596,300  
Retained earnings     3,575,996       3,195,818  
Treasury stock, at cost (39,515,303 and 41,220,920 shares)     (1,564,178 )     (1,631,694 )
Accumulated other comprehensive loss     (18,283 )     (19,484 )
Total DaVita Inc. shareholders’ equity     2,537,421       2,141,075  
Noncontrolling interests not subject to put provisions     132,964       127,050  
Total equity     2,670,385       2,268,125  
    $ 10,824,112     $ 8,892,172  
 
 
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
    Three months ended   Nine months ended September 30, 2012
    September 30,

2012

  June 30,

2012

  September 30,

2011

 
1. Consolidated Financial Results:                
Consolidated operating revenues   $ 2,023     $ 1,984     $ 1,808     $ 5,927  
Consolidated net operating revenues   $ 1,963     $ 1,930     $ 1,758     $ 5,759  
Operating income   $ 340.9     $ 247.9     $ 318.7     $ 909.5  
Operating income excluding the legal proceeding contingency accrual and related expenses(1)   $ 340.9     $ 325.9     $ 318.7     $ 987.5  
Operating income margin     16.9 %     12.5 %     17.6 %     15.3 %
Operating income margin excluding the legal proceeding contingency accrual and related expenses(1)     16.9 %     16.4 %     17.6 %     16.7 %
Net income attributable to DaVita Inc.   $ 144.7     $ 95.3     $ 135.4     $ 380.2  
Net income attributable to DaVita Inc. excluding the legal proceeding contingency accrual and related expenses(1)   $ 144.7     $ 142.9     $ 135.4     $ 427.8  
Diluted net income per share attributable to DaVita Inc.   $ 1.50     $ 0.99     $ 1.42     $ 3.96  
Diluted net income per share attributable to DaVita Inc.(1), excluding the legal proceeding contingency accrual and related expenses   $ 1.50     $ 1.49     $ 1.42     $ 4.46  
                 
2. Consolidated Business Metrics:                
Expenses                
Patient care costs as a percent of consolidated operating revenues(2)     66.3 %     66.1 %     65.8 %     66.1 %
General and administrative expenses as a percent of consolidated operating revenues(2)     9.9 %     10.8 %     10.1 %     10.5 %
                 
Total provision for uncollectible accounts as a percent of consolidated operating revenues     3.1 %     2.8 %     2.9 %     2.9 %
                 
Consolidated effective tax rate     36.4 %     36.2 %     36.4 %     36.4 %
Consolidated effective tax rate attributable to DaVita Inc.(1)     40.5 %     41.5 %     40.5 %     40.8 %
                 
3. Segment Financial Results: (dollar amounts rounded to nearest million)                
Operating revenues                
Dialysis and related lab services patient service operating revenues   $ 1,842     $ 1,813     $ 1,672     $ 5,423  
Less: Provision for uncollectible accounts related to patient service operating revenues     (60 )     (54 )     (50 )     (167 )
Dialysis and related lab services net patient service operating revenues   $ 1,782     $ 1,759     $ 1,622     $ 5,256  
Other revenues     3       3       3       8  
Total net dialysis and related lab services operating revenues     1,785       1,762       1,625       5,264  
Other – Ancillary services and strategic initiatives     180       170       135       503  
Other – Ancillary services and strategic initiatives net patient service operating revenues (related to international dialysis operations and a vascular access clinic)     5       5       2       12  
Total net segment operating revenues     1,970       1,937       1,762       5,779  
Elimination of intersegment revenues     (7 )     (7 )     (4 )     (20 )
Total net consolidated operating revenues   $ 1,963     $ 1,930     $ 1,758     $ 5,759  
 
 
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA—continued
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
    Three months ended   Nine months ended September 30, 2012  
    September 30,

2012

  June 30,

2012

  September 30,

2011

   
3. Segment Financial Results: (dollar amounts rounded to nearest million)(continued)                  
Operating Income                  
Dialysis and related lab services operating income   $ 361     $ 286     $ 333     $ 1,002  
Other – Ancillary services and strategic initiatives, including international dialysis operations operating losses     (11 )     (19 )     (3 )     (48 )
Total segment operating income   $ 350     $ 267     $ 330     $ 954  
Reconciling items:                  
Other corporate level general and administrative expenses including stock-based compensation     (12 )     (22 )     (13 )     (53 )
Equity investment income     3       3       2       8  
Consolidated operating income   $ 341     $ 248     $ 319     $ 909  
                   
4. Segment Business Metrics:                  
Dialysis and related lab services                  
Volume                  
Treatments     5,550,645       5,451,901       5,008,094       16,316,821  
Number of treatment days     78.0       78.0       79.0       234.0  
Treatments per day     71,162       69,896       63,394       69,730  
Per day year over year increase     12.3 %     14.3 %     9.6 %     13.5 %
Non-acquired growth year over year     4.4 %     4.7 %     5.0 %     4.9 %
                   
Operating revenues before provision for uncollectible accounts                  
Dialysis and related lab services revenue per treatment   $ 331.93     $ 332.67     $ 333.86     $ 332.34  
Per treatment (decrease) increase from previous quarter     (0.2 %)     0.1 %     0.5 %    
Per treatment (decrease) increase from previous year     (0.6 %)     0.1 %     (1.5 %)     0.4 %
Percent of consolidated revenues     91.0 %     91.3 %     92.5 %     91.4 %
                   
Expenses                  
Patient care costs                  
Percent of total segment operating revenues     64.3 %     64.1 %     64.5 %     64.1 %
Per treatment   $ 213.90     $ 213.68     $ 215.66     $ 213.25  
Per treatment increase (decrease) from previous quarter     0.1 %     0.7 %     (3.2 %)    
Per treatment decrease from previous year     (0.8 %)     (4.1 %)     (7.4 %)     (3.3 %)
                   
General and administrative expenses                  
Percent of total segment operating revenues     8.6 %     8.6 %     8.8 %     8.8 %
Per treatment   $ 28.55     $ 28.80     $ 29.28     $ 29.23  
Per treatment (decrease) increase from previous quarter     (0.9 %)     (5.2 %)     9.3 %    
Per treatment (decrease) increase from previous year     (2.5 %)     7.5 %     10.0 %     5.8 %
   
 
DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA—continued
(unaudited)
(dollars in millions, except for per share and per treatment data)
 
    Three months ended   Nine months ended September 30, 2012
    September 30,

2012

  June 30,

2012

  September 30,

2011

 
5. Cash Flow:                
Operating cash flow   $ 366.6     $ 202.1     $ 495.2     $ 900.6
Operating cash flow, last twelve months   $ 1,051.3     $ 1,179.8     $ 1,149.9      
Free cash flow(1)   $ 271.4     $ 111.4     $ 423.1     $ 632.7
Free cash flow, last twelve months(1)   $ 664.8     $ 816.5     $ 860.2      
Capital expenditures:                
Routine maintenance/IT/other   $ 63.7     $ 66.6     $ 51.1     $ 185.9
Development and relocations   $ 64.7     $ 71.4     $ 45.7     $ 193.0
Acquisition expenditures   $ 72.3     $ 214.1     $ 775.9     $ 419.1
                 
6. Accounts Receivable:                
Net receivables   $ 1,248     $ 1,250     $ 1,165      
DSO     59       60       59      
7. Debt and Capital Structure:                
Total debt(3)   $ 5,745     $ 4,505     $ 4,508      
Net debt, net of cash and cash equivalents including restricted cash at September 30, 3012(3)   $ 4,094     $ 4,232     $ 3,967      
Leverage ratio (see calculation on page 11)   2.61x   2.70x   2.73x    
Overall weighted average effective interest rate during the quarter     5.31 %     5.27 %     5.30 %    
Overall weighted average effective interest rate at end of the quarter     5.38 %     5.28 %     5.27 %    
Weighted average effective interest rate on the Senior Secured Credit Facilities at end of the quarter     4.61 %     4.61 %     4.61 %    
Fixed and economically fixed interest rates as a percentage of our total debt(4)     66 %     57 %     57 %    
Share repurchases   $ -     $ -     $ 7.3      
                 
8. Clinical: (quarterly averages)                
Dialysis adequacy -% of patients with Kt/V > 1.2 at the end of the quarter     98 %     98 %     97 %    
Patients with arteriovenous fistulas placed     71 %     70 %     69 %    
 

_________________

(1) These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see attached reconciliation schedules.

(2) Consolidated percentages of revenues are comprised of the dialysis and related lab services business, other ancillary services and strategic initiatives, stock-based compensation expenses, and in case of general and administrative expenses, includes other certain corporate level general and administrative expenses.

(3) The reported balance sheet amounts at September 30, 2012June 30, 2012 and September 30, 2011, are net of $6.6 million$7.0 million and $8.3 million, respectively, of debt discounts associated with our Term Loan B and our Term Loan A-2.

(4) The Term Loan A-2 and Term Loan B are subject to LIBOR floors of 1.00% and 1.50%, respectively. Because LIBOR, for all periods presented above, was lower than either of these floors, the interest rates on the Term Loan A-2 and the Term Loan B are set at their respective floors. At such time as the LIBOR-based component of our interest rate exceeds 1.00% on the Term Loan A-2 and 1.50% on the Term Loan B, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan A-2, as well as for the Term Loan B, but limited to a maximum rate of 4.00% on $1.25 billion of outstanding principal debt on the Term Loan B. The remaining $469 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%.

DAVITA INC.
SUPPLEMENTAL FINANCIAL DATA—continued
(unaudited)
(dollars in thousands)

Note 1: Calculation of the Leverage Ratio

Under the Company’s Senior Secured Credit Facilities (Credit Agreement), the leverage ratio is defined as all funded debt plus the face amount of all letters of credit issued, minus cash and cash equivalents, divided by “Consolidated EBITDA.” The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A and revolving line of credit under the Credit Agreement by establishing the margin over the base interest rate (LIBOR) that is applicable. The following leverage ratio was calculated using “Consolidated EBITDA” as defined in the Credit Agreement. The calculation below is based on the last twelve months of “Consolidated EBITDA,” pro forma for routine acquisitions that occurred during the period. The Company’s management believes the presentation of “Consolidated EBITDA” is useful to investors to enhance their understanding of the Company’s leverage ratio under its Credit Agreement.

 
    Rolling twelve months
    ended September 30,
    2012
Net income attributable to DaVita Inc.   $ 528,301
Income taxes   353,047
Interest expense   236,727
Depreciation and amortization   307,355
Noncontrolling interests and equity investment income, net   105,394
Stock-based compensation   47,183
Other items   23,624
“Consolidated EBITDA”   $ 1,601,631
     
    September 30, 2012
Total debt, excluding debt discount of $6.6 million   $ 5,745,136
Letters of credit issued   87,953
    5,833,089
Less: Cash and cash equivalents and including restricted cash   (1,650,962)
Consolidated net debt   $ 4,182,127
Last twelve months “Consolidated EBITDA”   $ 1,601,631
Leverage ratio   2.61x
 

In accordance with the Credit Agreement, the Company’s leverage ratio cannot exceed 4.25 to 1.0 as of September 30, 2012. At that date the Company’s leverage ratio did not exceed 4.25 to 1.0.

DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

1. Net income attributable to DaVita Inc. excluding an after-tax legal proceeding contingency accrual and related expenses and an after-tax non-cash goodwill impairment charge and diluted earnings per share attributable to DaVita Inc. excluding an after-tax legal proceeding contingency accrual and related expenses and an after-tax non-cash goodwill impairment charge.

We believe that net income attributable to DaVita Inc. excluding an after-tax legal proceeding contingency accrual and related expenses and an after-tax non-cash goodwill impairment charge enhances a user’s understanding of our normal net income attributable to DaVita Inc. and diluted earnings per share attributable to DaVita Inc. for these periods by providing a measure that is meaningful because it excludes an unusual charge for a legal proceeding contingency accrual that resulted from an agreement we reached in principle to settle federal program claims relating to our historical Epogen practices during the second quarter of 2012 and also excludes a non-cash goodwill impairment charge that resulted from a decrease in the implied fair value of goodwill below its carrying amount associated with our infusion therapy business during the second quarter of 2011 and accordingly, is more comparable to prior periods and indicative of consistent net income attributable to DaVita Inc. and diluted earnings per share to DaVita Inc. These measures are not measures of financial performance under United States generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income attributable to DaVita Inc., and diluted earnings per share attributable to DaVita Inc.

 
Net income attributable to DaVita Inc. excluding an after-tax legal proceeding contingency accrual and related expenses and an after-tax non-cash goodwill impairment charge:   Three months ended   Nine months ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2012   2012   2011   2012   2011
Net income attributable to DaVita Inc.   $ 144,721   $ 95,337     $ 135,361   $ 380,178     $ 329,878  
Add:                    
Legal proceeding contingency accrual and related expenses       78,000         78,000    
Non-cash goodwill impairment charge             24,000  
Less: Related income tax       (30,420 )       (30,420 )     (9,600 )
    $ 144,721   $ 142,917     $ 135,361   $ 427,758     $ 344,278  
 
 
Diluted earnings per share attributable to DaVita Inc. excluding an after-tax legal proceeding contingency accrual and related expenses and an after-tax non-cash goodwill impairment charge:   Three months ended   Nine months ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2012   2012   2011   2012   2011
Diluted earnings per share attributable to DaVita Inc.   $ 1.50   $ 0.99   $ 1.42     3.96   $ 3.40
Add:                    
Legal proceeding contingency accrual and related expenses       0.50       0.50  
Non-cash goodwill impairment charge             0.14
    $ 1.50   $ 1.49   $ 1.42   $ 4.46   $ 3.54
 

DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

2. Operating income excluding a pre-tax legal proceeding contingency accrual and related expenses and a pre-tax non-cash goodwill impairment charge.

We believe that operating income excluding a pre-tax legal proceeding contingency accrual and related expenses and a pre-tax non-cash goodwill impairment charge enhances a user’s understanding of our normal operating income for these periods by providing a measure that is meaningful because it excludes an unusual charge for a legal proceeding contingency accrual that resulted from an agreement we reached in principle to settle federal program claims relating to our historical Epogen practices during the second quarter of 2012 and also excludes a non-cash goodwill impairment charge that resulted from a decrease in the implied fair value of goodwill below its carrying amount associated with our infusion therapy business during the second quarter of 2011 and accordingly, is more comparable to prior periods and indicative of consistent operating income. This measure is not a measure of financial performance under GAAP and should not be considered as an alternative to operating income.

 
Operating income excluding a pre-tax legal proceeding contingency accrual and related expenses and a pre-tax non-cash goodwill impairment charge:   Three months ended   Nine months ended
    September 30,   June 30,   September 30,   September 30,   September 30,
    2012   2012   2011   2012   2011
Operating income   $ 340,859   $ 247,882   $ 318,712   $ 909,461   $ 800,670
Add:                    
Legal proceeding contingency accrual and related expenses       78,000       78,000  
Non-cash goodwill impairment charge             24,000
    $ 340,859   $ 325,882   $ 318,712   $ 987,461   $ 824,670
 

DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

3. Effective Income Tax Rates

We believe that reporting the effective income tax rate attributable to DaVita Inc. enhances an investor’s understanding of DaVita’s effective income tax rate for the periods presented because it excludes noncontrolling owners’ income that primarily relates to non-tax paying entities and accordingly is more comparable to prior periods presentations regarding DaVita’s effective income tax rate and is meaningful to an investor to fully understand the related income tax effects on DaVita Inc.’s operating results. This is not a measure under GAAP and should not be considered as an alternative to the effective income tax rate calculated in accordance with GAAP.

Effective income tax rate as compared to the effective income tax rate attributable to DaVita Inc. is as follows:

 
    Three months ended   Nine months ended September 30, 2012
    September 30,

2012

  June 30,

2012

  September 30,

2011

 
Income from continuing operations before income taxes   $ 271,184     $ 188,013     $ 258,662     $ 719,575  
Income tax expense   $ 98,634     $ 68,009     $ 94,204     $ 262,138  
Effective income tax rate     36.4 %     36.2 %     36.4 %     36.4 %
 
 
    Three months ended   Nine months ended September 30, 2012
    September 30,

2012

  June 30,

2012

  September 30,

2011

 
Income from continuing operations before income taxes   $ 271,184     $ 188,013     $ 258,662     $ 719,575  
Less: Noncontrolling owners’ income primarily attributable to non-tax paying entities     (27,954 )     (25,051 )     (26,604 )     (77,888 )
Income before income taxes attributable to DaVita Inc.   $ 243,230     $ 162,962     $ 232,058     $ 641,687  
                 
Income tax expense     98,634       68,009     $ 94,204     $ 262,138  
Less: Income tax attributable to noncontrolling interests     (125 )     (384 )     (119 )     (629 )
Income tax attributable to DaVita Inc.   $ 98,509     $ 67,625     $ 94,085     $ 261,509  
                 
Effective income tax rate attributable to DaVita Inc.     40.5 %     41.5 %     40.5 %     40.8 %
 

DAVITA INC.
RECONCILIATIONS FOR NON-GAAP MEASURES
(unaudited)
(dollars in thousands)

4. Free cash flow

Free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests and capital expenditures for routine maintenance and information technology. We believe free cash flow is a useful adjunct to cash flow from operating activities and other measurements under GAAP, since free cash flow is a meaningful measure of our ability to fund acquisition and development activities and meet our debt service requirements. In addition, free cash flow excluding distributions to noncontrolling interests provides an investor with an understanding of free cash flows that are attributable to DaVita Inc. Free cash flow is not a measure of financial performance under GAAP and should not be considered as an alternative to cash flows from operating, investing or financing activities, as an indicator of cash flows or as a measure of liquidity.

 
    Three months ended   Nine months ended September 30, 2012
    September 30,

2012

  June 30,

2012

  September 30,

2011

 
Cash provided by operating activities   $ 366,634     $ 202,105     $ 495,194     $ 900,613  
Less: Distributions to noncontrolling interests     (31,500 )     (24,073 )     (20,985 )     (81,978 )
Cash provided by operating activities attributable to DaVita Inc.     335,134       178,032       474,209       818,635  
Less: Expenditures for routine maintenance and information technology     (63,718 )     (66,603 )     (51,107 )     (185,930 )
Free cash flow   $ 271,416     $ 111,429     $ 423,102     $ 632,705  
 
 
    Rolling 12-Month Period
    September 30,   June 30,   September 30,
    2012   2012   2011
Cash provided by operating activities   $ 1,051,272     $ 1,179,832     $ 1,149,938  
Less: Distributions to noncontrolling interests     (115,223 )     (104,708 )     (89,887 )
Cash provided by operating activities attributable to DaVita Inc.     936,049       1,075,124       1,060,051  
Less: Expenditures for routine maintenance and information technology     (271,234 )     (258,623 )     (199,860 )
Free cash flow   $ 664,815     $ 816,501     $ 860,191  
 

 

Source: DaVita Inc.

DaVita Inc.
Jim Gustafson, 310-536-2585
Investor Relations


Contact Investor Relations

For media inquiries, please contact:

Media Kit

Kate Stabrawa
2000 16th Street
Denver, CO 80202
(303) 876-7527